Pasar al contenido principal

RED DE INVESTIGACION EN INFLAMMASOMA Y PIROPTOSIS EN ENFERMEDADES CRONICAS Y CANCER

RED2022-134511-T

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Redes Investigación /Redes Excelencia
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE MURCIA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Novel insights into the clinical features, genetic spectrum and clonal evolution of patients carrying NLRP3 mosaicism

  • Bonet, Núria
  • Pesqué, David
  • Giménez Arnau, Anna Maria
  • Laayouni, Hafid, 1968-
  • Fornas Carreño, Oscar
  • Aróstegui Gorospe, Juan Ignacio
NLRP3 mosaicism is a well-established mechanism causing the monogenic autoinflammatory disease named cryopyrin-associated periodic syndromes (CAPS). The number of reported patients with NLRP3 mosaicism is small, and the knowledge about the long-term disease behavior is limited. Herein we assembled the largest cohort of individuals with NLRP3 mosaicism reported to date to obtain additional evidence that strengthens the understanding of this disease. The novel genetic data were obtained by using Sanger and next-generation sequencing methods, whereas in vitro analyses determined the functional consequences of detected variants. A total of seventeen individuals with NLRP3 mosaicism were enrolled, with 16/17 experiencing different CAPS phenotypes. An overrepresentation of late-onset forms was detected (37.5%). Overall, clinical manifestations, analytical results, and outcomes of treatments were markedly similar to those detected in patients with germline variants. A large mutational diversity was identified, with 16 different variants among 17 individuals. Two main patterns of mosaicism (extended vs. myeloid-restricted) were detected, with the last one overrepresented in the late-onset group. The evaluation of mosaicism over time identified three different patterns, being the group with stable mosaicism the largest one. Collected evidence supports the marked similarities among patients carrying somatic or germline NLRP3 variants. The overrepresentation of NLRP3 mosaicism in late-onset forms should be considered in patients with inflammatory manifestations starting in adulthood. Analysis of mosaicism at the biological level confirms the two known patterns of corporal distribution and reveals that mosaicism remains stable over time in most patients, but it may also vary during the course of the disease., This work has been partially funded by: • PID2021-125106OB-C31 (JIA), PID2020-116709RB-I00 (PP), CNS2022-135101 (PP), PID2023-147531OB-I00 (PP), PID2021-125106OB-C32 (FC), RED2022-134511-T (PP, JIA) and PID2021-125106OB-C33 (OF) grants from the Ministerio de Ciencia e Innovación (MCIN) | Agencia Estatal de Investigación (AEI) | https://doi.org/10.13039/501100011033 | Fondo Europeo de Desarrollo Regional (FEDER), UE | European Union «Next Generation EU/PRTR». • AC21_2/00042 (JIA) and IFI22/00031 (JG-V) grants from the Instituto de Salud Carlos III co-funded by Unión Europea Next Generation EU | Mecanismo para la Recuperación y la Resiliencia (MRR) | Plan de Recuperación, Transformación y Resiliencia (PRTR). • 2021SGR01093 | Agència de Gestió d’Ajuts Universitaris i de Recerca | Generalitat de Catalunya (FC). • 21897/PI/22 (PP) and 21214/FPI/19 (LH-N) | Fundación Séneca, Región de Murcia, Spain.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Datos de investigación Set de datos (Dataset)

Quinolyl nitrone derivative QN23 protects from auditory cell oxidative injury and noise-induced hearing loss

  • Murillo-Cuesta, Silvia
  • Contreras, Julio
  • Chioua, Mourad
  • García Montoya, Carmen
  • Rodriguez-de la Rosa, Lourdes
  • Méndez-Grande, Inés
  • Piotrowsk, Dorota G.
  • Głowacka, Iwona E.
  • Varela-Nieto, Isabel
  • Contelles, José-Marco
FIGURE 1_DATASET and TABLE 1_DATASET: HEI-OC1 cells were cultured in DMEM medium supplemented with 10% fetal bovine serum (Gibco-Thermo Fisher Scientific, Waltham, MA, USA) and 2.5ug/mL Amphotericin B (A2942, Sigma-Aldrich, Saint Louis, MO, USA). Nitrones QN23, F2 and TNs were dissolved in absolute EtOH ≥ 99.5% (#107017; Merck, Kenilworth, NJ, USA) at 20, 5 or 10 mM (stock solution), respectively, and sonicated 10 minutes at 37ºC in a Branson Bransonic® M Mechanical Bath (Emerson Electric). Then, they were tested first for ototoxicity at different concentrations in DMEM without FBS, in the absence or presence of H2O2 (range 1-1.4 mM) and subsequently their efficacy. Cell viability was evaluated by the XTT method by following the manufacturer´s instructions (Cell Proliferation Kit II, Roche Molecular Systems). Absorbance measurements at 450 and 660 nm were taken with the VERSAmax plate reader (Molecular Devices, San Jose, CA, USA) at 4, 6 and 23 hours after the addition of XTT. All reading times rendered similar results. Cell viability was calculated as follows: Specific absorbance = [Abs450 nm (test) - Abs450 nm (mock)] - Abs660 nm (test). Control wells without seeded cells were used as reference. FIGURE 2_DATASET: Hearing was assessed by recording auditory brainstem evoked potentials (ABR) before (baseline) and 1, 14 and 28 days after noise exposure. Click and tone burst stimuli (4, 8, 16, 24 and 32 kHz) were presented with an MF1 magnetic speaker (TDT) from 90 to 20 dB SPL in 5–10 dB SPL steps. Click stimuli were 0.1 ms and tone burst stimuli were 5 ms in duration (2.5 ms each for rise and decay, without plateau). The threshold of click-evoked and tone-evoked ABRs, peak latencies, and amplitudes were determined. Mice were exposed to 2–20 kHz, 105 dB SPL noise for 30 minutes. FIGURE 4_DATASET and FIGURE 5_DATASET: Cochlear RNA was extracted with the RNeasy kit (QIAGEN, Hilden, Germany). Quality and quantity of RNA were determined with an Agilent Bioanalyzer 2100 (Agilent Technologies Santa Clara, CA, USA). RNA from three animals per experimental group was pooled. cDNA was then generated by reverse transcription (High-Capacity cDNA Reverse Transcription Kit; Applied Biosystems, Foster City, CA, USA) and gene expression was analyzed in triplicate by qPCR on Applied Biosystems 7900 HT using TaqMan Gene Expression Assays (Applied Biosystems) for Nrf2, Hmox1, Nqo1, Nox4, Nlrp3, Tnfa, Tgfb, Il1b, Il6, Il10, Kim1 and Rplp0 was used as endogenous housekeeping control gene Dusp1 (Supplementary Table 1). Gene expression was calculated as 2−ΔΔCt (RQ)., Oxidative stress is a key pathogenic mechanism in noise-induced hearing loss, occurring when the production of free radicals in the cochlea overwhelms its antioxidant defenses. Thus, antioxidant molecules, including N-acetyl-L-cysteine, acetyl-L-carnitine, resveratrol, HPN-07 and 4-OHPBN nitrones have been explored as otoprotective agents with limited success. A novel quinolyl-nitrone derivative QN23 has been shown to suppress oxidative stress in ischemic stroke. In this study, we show that QN23 was not ototoxic and protected from oxidative stress both in vitro in the cochlear HEI-OC1 cell line and in vivo in mice. QN23 increased HEI-OC1 cell survival after H₂O₂-induced oxidative stress showing better effectiveness than N-acetyl-L-cysteine. Systemic administration of QN23 in mice was well-tolerated and significantly reduced acute auditory threshold shifts one day post-noise exposure. The protective effects of QN23 were dose- and time-dependent, with optimal results observed when administered twice daily for three days, starting one hour prior to noise exposure. This protection was associated to the duration of the treatment. QN23 normalized the expression of cochlear genes associated with oxidative stress and inflammation such us Nrf2, Hmox1, Nqo1, Nlrp3, Tnfa, Il1b, Dusp1 and Kim1, among others, counteracting immediate noise-induced molecular alterations. These results suggest that QN23 effectively mitigates cochlear oxidative damage and that early intervention can block critical molecular changes induced by noise, thereby preserving hearing., MINECO/FEDER PID2023-147347OB-I00 (PROHEAR) FGCSIC/PSL-INTERREG/FEDER 0551_PSL_6_E POCTEP (NITROPROHEAR) COST Action/EU CA20121 (BenBedPhar) CIBERER ERP24P5AC761-ACCI23-19-761 (SENSORARE) Comunidad de Madrid P2022/BMD-7236 MINA-CM Madrid Innovative Neurotech Alliance MICIN/AEI RED2022-134511-T (REDINFLAMA) Medical University of Lodz internal funds (503/3-014-01/503-31-001)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

4-octyl itaconate reduces human NLRP3 inflammasome constitutive activation with the cryopyrin-associated periodic syndrome p.R262W, p.D305N and p.T350M variants

  • Molina-López, Cristina
  • Hurtado-Navarro, Laura
  • O'Neill, Luke A. J.
  • Pelegrín, Pablo
Cryopyrin-associated periodic syndrome (CAPS) is a condition characterized by dominant genetic variants in the NLRP3 gene, which lead to the formation of constitutively active inflammasomes. These inflammasomes play a crucial role in CAPS patients' inflammatory episodes, these being primarily driven by the production of interleukin (IL)-1b. Although treatment with IL-1 blockers is effective for CAPS, some patients develop refractory responses and adverse reactions to these therapies. Consequently, there is a need for novel treatments for CAPS patients. Promising candidates are the derivatives of itaconate, which have been shown to impair NLRP3 inflammasome activation and IL-1β release in blood mononuclear cells from CAPS patients. In this study, we provide insight into the inhibitory mechanisms by which the itaconate derivative 4-octyl itaconate (4-OI) acts on NLRP3 that has different gain-of-function mutations (p.R262W, p.D305N and p.T350M) associated with CAPS. Notably, 4-OI effectively blocks the basal auto-activation of the inflammasome formed by NLRP3 p.R262W, p.D305N and p.T350M variants, which in turn reduces caspase-1 activation, gasdermin D processing, and IL-18 release. Furthermore, after lipopolysaccharide priming of macrophages, 4-OI also decreases IL-1β gene expression and release. Overall, 4-OI impairs CAPS-associated inflammasome function at multiple levels, meaning that therapeutic agents based on itaconate could be a promising therapeutic approach to managing inflammatory episodes in CAPS patients carrying p.R262W, p.D305N or p.T350M variants., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This work was supported by grants from MCIN/AEI/https://doi.org/10.13039/501100011033(grants PID2020-116709RB-I00, CNS2022-135105 and RED2022-134511-T to PP), Fundación Séneca (grant 21897/PI/22 to PP), the Instituto Salud Carlos III (grant AC22/00009 to PP). L.H-N. was supported by the fellowship 21214/FPI/19 (Fundación Séneca, Región de Murcia, Spain) and CM-L by was funded by the fellowship PRE2018-086824 (Ministerio de Economía y Competitividad)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Atrial Myopathy and Heart Failure: Immunomolecular Mechanisms and Clinical Implications

  • Gil Fernández, Marta
  • Bueno Sen, Andrea
  • Cantolla Pablo, Paula
  • Val Blasco, Almudena
  • Ruiz Hurtado, Gema
  • Delgado, Carmen
  • Cubillos, Carolina
  • Boscá, Lisardo
  • Fernández Velasco, María
Heart failure (HF) remains a major global health challenge defined by the inability of the heart to adequately meet systemic metabolic requirements. While ventricular dysfunction has traditionally been the primary focus in both conceptual and clinical frameworks of HF, emerging evidence highlights atrial myopathy—covering structural, functional, electrical, metabolic, and neurohormonal remodeling—as a central yet often overlooked contributor to disease progression across the HF spectrum. This review offers a comprehensive overview of the molecular and cellular mechanisms underlying atrial remodeling, with a focus on inflammation and innate immune activation as key pathogenic mediators. Among pattern recognition receptors, Toll-like receptors (TLRs) and NOD-like receptors (NLRs) play crucial roles in translating myocardial stress into pro-inflammatory, profibrotic, and pro-arrhythmic signals that exacerbate HF. By combining experimental and clinical evidence, we emphasize atrial myopathy as both a biomarker and an active driver of HF deterioration, advocating for the inclusion of atrial-targeted diagnostics and immunomodulatory therapies in future HF treatment approaches. Such a paradigm shift holds significant potential for improved risk stratification, arrhythmia prevention, attenuation of structural remodeling, and ultimately, better prognosis and clinical outcomes in this increasingly common syndrome., This work was funded by the Spanish Ministry of Science and Innovation (MICIN/AEI/10.13039/501100011033) through grants PID2023-148933OB-I00 and CNS2023-145161, and the REDINFLAMA network (grant RED2022-134511-T); by the Instituto de Salud Carlos III (ISCIII) through grants PI20/01482, PI23/01014, F21/00259, CM23/00121, CD22/00055, PMP22/00098, PT23/00028, and by CIBERCV (Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares). Funding was also provided by the European Regional Development Fund (ERDF), the European Social Fund (ESF), and the COMETA-Red (Consejo Superior de Investigaciones Científicas, CSIC). Additional support was provided by the Spanish Society of Cardiology—Translational Project 2019, and the Heart Rhythm Association (SEC, Spain) through the Asociación Insuficiencia Cardiaca (Trasplante Cardiaco) Project 20203. A.V.B. was supported by a Sara Borrell postdoctoral fellowship (CD22/00055), funded by the Instituto de Salud Carlos III (ISCIII), the European Union—NextGenerationEU, and the Spanish Recovery, Transformation and Resilience Plan (PRTR)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Crosstalk between NLRP3 Signaling and Histone Deacetylases in Inflammasome-Driven Diseases

  • Tan, Kathrin
  • Rodríguez-Fernández, M. Mercedes
  • Keuler, Tim
  • Hansen, Finn K.
  • Gütschow, Michael
  • Weindl, Günther
  • Marco-Contelles, José
The NLRP3 inflammasome is a validated therapeutic target in inflammatory, metabolic, and neurodegenerative diseases. Epigenetic regulators, particularly histone deacetylases (HDACs), have emerged as key modulators of inflammasome priming and activation. Recent advances in medicinal chemistry have provided new chemical modalities for the mechanistic interrogation and the potential therapeutic modulation of NLRP3 signaling. This Perspective dissects the mechanistic interface between HDAC-dependent epigenetic control and NLRP3 signaling and highlights emerging chemical tools, including isoform-selective inhibitors and targeted protein degraders. We discuss the challenges of isoform selectivity, species-specific differences, and the therapeutic potential of HDAC-based strategies to attenuate aberrant NLRP3 activity while minimizing off-target effects. Understanding this epigenetic-inflammasome crosstalk may provide a framework for translating epigenetic modulation into innovative treatments for inflammasome-driven diseases., The work of F.K.H., M.G., and G.W. is funded by the DFG GRK2873 (494832089). J.M.-C thanks AEI (Government of Spain) for support (Grants PID2019-105813RB-C21, PID2022-136530OB-I00, and RED2022-134511-T). M.M.R.F. thanks Ignacio BenitoGómezforhishelpintheanalysisofthe information retrieved by J.M.-C. The TOC graphic and Figures 3 − ■ 5 were created with Biorender.com., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Novel insights into the clinical features, genetic spectrum and clonal evolution of patients carrying NLRP3 mosaicism

  • Bonet, Núria
  • Pesqué, David
  • Giménez Arnau, Anna Maria
  • Laayouni, Hafid, 1968-
  • Fornas Carreño, Oscar
  • Aróstegui Gorospe, Juan Ignacio
NLRP3 mosaicism is a well-established mechanism causing the monogenic autoinflammatory disease named cryopyrin-associated periodic syndromes (CAPS). The number of reported patients with NLRP3 mosaicism is small, and the knowledge about the long-term disease behavior is limited. Herein we assembled the largest cohort of individuals with NLRP3 mosaicism reported to date to obtain additional evidence that strengthens the understanding of this disease. The novel genetic data were obtained by using Sanger and next-generation sequencing methods, whereas in vitro analyses determined the functional consequences of detected variants. A total of seventeen individuals with NLRP3 mosaicism were enrolled, with 16/17 experiencing different CAPS phenotypes. An overrepresentation of late-onset forms was detected (37.5%). Overall, clinical manifestations, analytical results, and outcomes of treatments were markedly similar to those detected in patients with germline variants. A large mutational diversity was identified, with 16 different variants among 17 individuals. Two main patterns of mosaicism (extended vs. myeloid-restricted) were detected, with the last one overrepresented in the late-onset group. The evaluation of mosaicism over time identified three different patterns, being the group with stable mosaicism the largest one. Collected evidence supports the marked similarities among patients carrying somatic or germline NLRP3 variants. The overrepresentation of NLRP3 mosaicism in late-onset forms should be considered in patients with inflammatory manifestations starting in adulthood. Analysis of mosaicism at the biological level confirms the two known patterns of corporal distribution and reveals that mosaicism remains stable over time in most patients, but it may also vary during the course of the disease., This work has been partially funded by: • PID2021-125106OB-C31 (JIA), PID2020-116709RB-I00 (PP), CNS2022-135101 (PP), PID2023-147531OB-I00 (PP), PID2021-125106OB-C32 (FC), RED2022-134511-T (PP, JIA) and PID2021-125106OB-C33 (OF) grants from the Ministerio de Ciencia e Innovación (MCIN) | Agencia Estatal de Investigación (AEI) | https://doi.org/10.13039/501100011033 | Fondo Europeo de Desarrollo Regional (FEDER), UE | European Union «Next Generation EU/PRTR». • AC21_2/00042 (JIA) and IFI22/00031 (JG-V) grants from the Instituto de Salud Carlos III co-funded by Unión Europea Next Generation EU | Mecanismo para la Recuperación y la Resiliencia (MRR) | Plan de Recuperación, Transformación y Resiliencia (PRTR). • 2021SGR01093 | Agència de Gestió d’Ajuts Universitaris i de Recerca | Generalitat de Catalunya (FC). • 21897/PI/22 (PP) and 21214/FPI/19 (LH-N) | Fundación Séneca, Región de Murcia, Spain.